Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator XXXX ointment (fingolimod) in NC/Nga @entity19 .

@entity483 @entity19 @entity57158 @entity5935 @entity20083 @entity1184 @entity1140
BACKGROUND: The increasing incidence and prevalence of @entity483 ( @entity483 ) demands new therapeutic approaches for treating the disease. We investigated the therapeutic efficacy of immunomodulator @entity20083 ointment (fingolimod) for mite-induced intractable @entity483 using an NC/Nga @entity19 model. METHODS: Female NC/Nga @entity19 that developed severe @entity483 were divided into four groups: (1) @entity20083 (0.001% @entity20083 ointment), (2) @entity1140 ( @entity57158 ointment) (3) @entity5935 ( @entity5935 ointment), and (4) ointment base (hydrophilic petrolatum), all of which received treatment six times per week. Therapeutic efficacy after two weeks was evaluated in terms of @entity483 severity, histochemical observations (epidermal @entity1184 , mast cell accumulation, and CD3(+) T cell infiltration), transepidermal water loss (TEWL), and epidermal barrier function (filaggrin expression). RESULTS: @entity5935 treatment showed little effect, confirming that the @entity483 was intractable. In the @entity20083 group, @entity483 improved significantly compared with the ointment base group, as did epidermal @entity1184 , mast cell accumulation, and CD3(+) T cell infiltration. In contrast, @entity483 in the @entity1140 and @entity5935 groups did not improve significantly, nor did epidermal @entity1184 or mast cell accumulation. Furthermore, in the @entity20083 group, TEWL decreased significantly compared with the ointment base group, and filaggrin expression significantly increased compared with the @entity5935 and ointment base groups. CONCLUSIONS: @entity20083 ointment is a promising candidate for treatment of intractable @entity483 . These findings also provide the first evidence that @entity20083 ointment ameliorates epidermal barrier function.
